https://orcid.org/0000-0002-2453-6278
References
- HaugenBR, AlexanderEK, BibleKC et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016).
- ShermanSI. Thyroid carcinoma. Lancet 361(9356), 501–511 (2003).
- MorrisLG, MyssiorekD. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am. J. Surg. 200(4), 454–461 (2010).
- KrolE, BrandtCT, Blakeslee-CarterJ et al. Vascular interventions in head and neck cancer patients as a marker of poor survival. J. Vasc. Surg. 69(1), 181–189 (2019).
- ManzoorNF, RussellJO, BrickerA et al. Impact of surgical resection on survival in patients with advanced head and neck cancer involving the carotid artery. JAMA Otolaryngol. Head Neck Surg. 139(11), 1219–1225 (2013).
- SchlumbergerM, TaharaM, WirthLJ et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015).
- GuoY, PangMC, TeoCE, ChngJK. Carotid artery involvement in advanced recurrent head and neck cancer: a case report and literature review. Ann. Vasc. Surg. 56, 355e311–355e315 (2019).
- MoritaniS. Appropriateness of subadventitial resection for invasion of the carotid artery by papillary thyroid carcinoma. World J. Surg. 43(2), 519–526 (2019).
- DanilovicDLS, CastroGJr, RoitbergFSR et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch. Endocrinol. Metab. 62(3), 370–375 (2018).
- GayS, MontiE, TrambaioloAntonelli C et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol. 15(24s), 13–19 (2019).
- HartlDM, GuerlainJ, BresuskinI et al. Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer. Eur. J. Surg. Oncol. 46(4 Pt A), 650–655 (2020).
- NavaCF, ScheffelRS, CristoAP et al. Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front Endocrinol (Lausanne). 10, 712 (2019).
- StewartKE, StrachanMWJ, SrinivasanD, MacNeillM, WallL, NixonIJ. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur. Thyroid J. 8(2), 102–107 (2019).
- TsuboiM, TakizawaH, AoyamaM, TangokuA. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int. J. Surg. Case Rep. 41, 89–92 (2017).
- IwasakiH, TodaS, ItoH et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep. Endocrinol. 2020, 6438352 (2020).
- CabanillasME, FerrarottoR, GardenAS et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7), 945–951 (2018).
- WangJR, ZafereoME, DaduR et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29(8), 1036–1043 (2019).
- StaubY, NishiyamaA, SugaY, FujitaM, MatsushitaR, YanoS. Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Anticancer Res. 39(7), 3871–3878 (2019).
- YooGH, HocwaldE, KorkmazH et al. Assessment of carotid artery invasion in patients with head and neck cancer. Laryngoscope 110(3 Pt 1), 386–390 (2000).
- YousemDM, HatabuH, HurstRW et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 195(3), 715–720 (1995).
- YuQ, WangP, ShiH, LuoJ. Carotid artery and jugular vein invasion of oral-maxillofacial and neck malignant tumors: diagnostic value of computed tomography. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 96(3), 368–372 (2003).